Compare Stocks: RDNT, PSNL, and CSTL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CSTL Castle Biosciences	$34.08 -2.6%	$26.73	$17.72 ▼ $44.28	$1.07B	0.98	532,871 shs	456,261 shs
PSNL Personalis	$17.08 -1.0%	$13.74	$4.65 ▼ $18.89	$1.81B	2.27	3.60 million shs	2.17 million shs
RDNT RadNet	$76.47 -0.5%	$66.46	$50.82 ▼ $85.84	$6.05B	1.36	758,927 shs	391,302 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CSTL Castle Biosciences	-2.63%	+5.45%	+39.44%	+54.14%	+59.63%
PSNL Personalis	-0.99%	+8.03%	+42.57%	+55.56%	+250.00%
RDNT RadNet	-0.51%	+1.23%	+24.32%	+38.26%	+8.36%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CSTL Castle Biosciences	$34.08 -2.6%	$26.73	$17.72 ▼ $44.28	$1.07B	0.98	532,871 shs	456,261 shs
PSNL Personalis	$17.08 -1.0%	$13.74	$4.65 ▼ $18.89	$1.81B	2.27	3.60 million shs	2.17 million shs
RDNT RadNet	$76.47 -0.5%	$66.46	$50.82 ▼ $85.84	$6.05B	1.36	758,927 shs	391,302 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CSTL Castle Biosciences	-2.63%	+5.45%	+39.44%	+54.14%	+59.63%
PSNL Personalis	-0.99%	+8.03%	+42.57%	+55.56%	+250.00%
RDNT RadNet	-0.51%	+1.23%	+24.32%	+38.26%	+8.36%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CSTL Castle Biosciences	2.80	Moderate Buy	$42.00	23.24% Upside
PSNL Personalis	2.20	Hold	$14.54	-14.90% Downside
RDNT RadNet	2.89	Moderate Buy	$88.00	15.08% Upside

Current Analyst Ratings Breakdown

Latest RDNT, PSNL, and CSTL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	PSNL Personalis	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$16.25
8/13/2026	RDNT RadNet	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/11/2026	RDNT RadNet	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$90.00 ➝ $94.00
8/7/2026	RDNT RadNet	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/3/2026	CSTL Castle Biosciences	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $44.00
7/31/2026	CSTL Castle Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/31/2026	RDNT RadNet	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/31/2026	CSTL Castle Biosciences	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$36.00
7/21/2026	PSNL Personalis	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/20/2026	PSNL Personalis	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$16.25
7/20/2026	PSNL Personalis	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$11.00 ➝ $16.25

(Data available from 8/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CSTL Castle Biosciences	$344.23M	3.02	$1.08 per share	31.44	$15.39 per share	2.21
PSNL Personalis	$69.67M	25.67	N/A	N/A	$2.25 per share	7.59
RDNT RadNet	$2.04B	2.95	$3.21 per share	23.84	$17.71 per share	4.32

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CSTL Castle Biosciences	-$24.16M	-$0.66	N/A	N/A	N/A	-5.43%	-4.15%	-3.45%	11/2/2026 (Estimated)
PSNL Personalis	-$81.27M	-$1.09	N/A	N/A	N/A	-153.84%	-46.47%	-35.30%	11/3/2026 (Estimated)
RDNT RadNet	-$18.65M	-$0.27	N/A	87.90	N/A	-0.93%	2.61%	0.91%	11/9/2026 (Estimated)

Latest RDNT, PSNL, and CSTL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	RDNT RadNet	$0.2014	$0.29	+$0.0886	$0.10	$610.87 million	$622.72 million
8/4/2026	Q2 2026	PSNL Personalis	-$0.2633	-$0.30	-$0.0367	-$0.30	$16.69 million	$22.36 million
7/30/2026	Q2 2026	CSTL Castle Biosciences	-$0.4070	-$0.07	+$0.3370	-$0.07	$86.23 million	$99.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CSTL Castle Biosciences	N/A	N/A	N/A	N/A	N/A
PSNL Personalis	N/A	N/A	N/A	N/A	N/A
RDNT RadNet	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CSTL Castle Biosciences	0.02	6.04	5.85
PSNL Personalis	N/A	5.28	5.08
RDNT RadNet	0.94	1.48	1.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CSTL Castle Biosciences	92.60%
PSNL Personalis	61.91%
RDNT RadNet	77.90%

Insider Ownership

Company	Insider Ownership
CSTL Castle Biosciences	6.10%
PSNL Personalis	4.20%
RDNT RadNet	5.14%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CSTL Castle Biosciences	540	30.55 million	28.69 million	Optionable
PSNL Personalis	400	104.72 million	100.32 million	Optionable
RDNT RadNet	11,264	78.70 million	74.65 million	Optionable

RDNT, PSNL, and CSTL Headlines

Recent News About These Companies

633,272 Shares in RadNet, Inc. $RDNT Purchased by Punch & Associates Investment Management Inc.

47 minutes ago | marketbeat.com

EFG International AG Purchases New Holdings in RadNet, Inc. $RDNT

2 hours ago | marketbeat.com

Bamco Inc. NY Invests $77.77 Million in RadNet, Inc. $RDNT

3 hours ago | marketbeat.com

Odyssean LLC Has $3.23 Million Holdings in RadNet, Inc. $RDNT

August 26 at 6:32 AM | marketbeat.com

Palisade Capital Management LP Invests $12.30 Million in RadNet, Inc. $RDNT

August 26 at 5:52 AM | marketbeat.com

Expect Equity LLC Takes Position in RadNet, Inc. $RDNT

August 26 at 4:23 AM | marketbeat.com

Paradigm Capital Management Inc. NY Makes New $9.58 Million Investment in RadNet, Inc. $RDNT

August 25 at 5:59 AM | marketbeat.com

Portland Investment Counsel Inc. Buys New Stake in RadNet, Inc. $RDNT

August 24 at 6:39 AM | marketbeat.com

BlackRock Inc. Takes Position in RadNet, Inc. $RDNT

August 24 at 3:35 AM | marketbeat.com

B. Metzler seel. Sohn & Co. AG Takes Position in RadNet, Inc. $RDNT

August 23, 2026 | marketbeat.com

JB Capital Partners LP Purchases Shares of 1,424,061 RadNet, Inc. $RDNT

August 22, 2026 | marketbeat.com

Deutsche Bank AG Purchases New Stake in RadNet, Inc. $RDNT

August 22, 2026 | marketbeat.com

Edmond DE Rothschild Holding S.A. Acquires Shares of 19,000 RadNet, Inc. $RDNT

August 21, 2026 | marketbeat.com

Robotti Robert Invests $7.46 Million in RadNet, Inc. $RDNT

August 19, 2026 | marketbeat.com

Bank of America Corp DE Boosts Position in RadNet, Inc. $RDNT

August 16, 2026 | marketbeat.com

RadNet (NASDAQ:RDNT) Raised to "Hold" at Zacks Research

August 15, 2026 | marketbeat.com

RadNet Registers Shares for See-Mode Milestone Resale

August 14, 2026 | tipranks.com

RadNet, Inc. (NASDAQ:RDNT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

August 14, 2026 | marketbeat.com

RadNet: Imaging And AI Keep The Bull Case Intact

August 12, 2026 | seekingalpha.com

RadNet (NASDAQ:RDNT) Stock Price Expected to Rise, Truist Financial Analyst Says

August 11, 2026 | marketbeat.com

RDNT Q2 Earnings & Sales Beat on Advanced Imaging, Guidance Raised

August 11, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RDNT, PSNL, and CSTL Company Descriptions

Castle Biosciences NASDAQ:CSTL

$34.08 -0.92 (-2.63%)

Closing price 08/26/2026 04:00 PM Eastern

Extended Trading

$34.10 +0.02 (+0.06%)

As of 04:13 AM Eastern

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Personalis NASDAQ:PSNL

$17.08 -0.17 (-0.99%)

Closing price 08/26/2026 04:00 PM Eastern

Extended Trading

$17.07 -0.01 (-0.08%)

As of 04:09 AM Eastern

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.

RadNet NASDAQ:RDNT

$76.47 -0.39 (-0.51%)

Closing price 08/26/2026 04:00 PM Eastern

Extended Trading

$76.78 +0.31 (+0.41%)

As of 07:01 AM Eastern

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RDNT, PSNL, and CSTL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RDNT, PSNL, and CSTL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RDNT, PSNL, and CSTL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RDNT, PSNL, and CSTL Company Descriptions

Castle Biosciences NASDAQ:CSTL

Personalis NASDAQ:PSNL

RadNet NASDAQ:RDNT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RDNT, PSNL, and CSTL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RDNT, PSNL, and CSTL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RDNT, PSNL, and CSTL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RDNT, PSNL, and CSTL Company Descriptions

Castle Biosciences NASDAQ:CSTL

Personalis NASDAQ:PSNL

RadNet NASDAQ:RDNT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools